Literature DB >> 22641360

Urological cancer: Chemoradiation superior in muscle-invasive bladder cancer.

Christian Weiss, Claus Rödel.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22641360     DOI： 10.1038/nrclinonc.2012.92

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.

Authors:  Arlene A Forastiere; Helmuth Goepfert; Moshe Maor; Thomas F Pajak; Randal Weber; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Clifford Chao; Glen Peters; Ding-Jen Lee; Andrea Leaf; John Ensley; Jay Cooper
Journal:  N Engl J Med       Date:  2003-11-27       Impact factor: 91.245

2.  15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment.

Authors:  Frens Steffen Krause; Bernhard Walter; Oliver Josef Ott; Lothar Häberle; Christian Weiss; Claus Rödel; Bernd Wullich; Rolf Sauer
Journal:  Anticancer Res       Date:  2011-03       Impact factor: 2.480

3.  Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience.

Authors:  Mutahir A Tunio; Altaf Hashmi; Abdul Qayyum; Rehan Mohsin; Ahmed Zaeem
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-09-22       Impact factor: 7.038

4.  Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients.

Authors:  Richard E Hautmann; Robert C de Petriconi; Christina Pfeiffer; Bjoern G Volkmer
Journal:  Eur Urol       Date:  2012-02-22       Impact factor: 20.096

5.  Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.

Authors: 
Journal:  Lancet       Date:  1996-10-19       Impact factor: 79.321

6.  Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.

Authors:  Jason A Efstathiou; Daphna Y Spiegel; William U Shipley; Niall M Heney; Donald S Kaufman; Andrzej Niemierko; John J Coen; Rafi Y Skowronski; Jonathan J Paly; Francis J McGovern; Anthony L Zietman
Journal:  Eur Urol       Date:  2011-11-12       Impact factor: 20.096

7.  Use of radical cystectomy for patients with invasive bladder cancer.

Authors:  John L Gore; Mark S Litwin; Julie Lai; Elizabeth M Yano; Rodger Madison; Claude Setodji; John L Adams; Christopher S Saigal
Journal:  J Natl Cancer Inst       Date:  2010-04-16       Impact factor: 13.506

Review 8.  Trimodality treatment and selective organ preservation for bladder cancer.

Authors:  Claus Rödel; Christian Weiss; Rolf Sauer
Journal:  J Clin Oncol       Date:  2006-12-10       Impact factor: 44.544

9.  Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.

Authors:  Nicholas D James; Syed A Hussain; Emma Hall; Peter Jenkins; Jean Tremlett; Christine Rawlings; Malcolm Crundwell; Bruce Sizer; Thiagarajan Sreenivasan; Carey Hendron; Rebecca Lewis; Rachel Waters; Robert A Huddart
Journal:  N Engl J Med       Date:  2012-04-19       Impact factor: 91.245

10.  Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results.

Authors:  Claus Rödel; Gerhard G Grabenbauer; Reinhard Kühn; Thomas Papadopoulos; Jürgen Dunst; Martin Meyer; Karl M Schrott; Rolf Sauer
Journal:  J Clin Oncol       Date:  2002-07-15       Impact factor: 44.544
  10 in total
  2 in total

1.  [Translational uroradio-oncology].

Authors:  S E Combs; J Debus
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

Review 2.  Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.

Authors:  Samuel A Funt; Jonathan E Rosenberg
Journal:  Nat Rev Clin Oncol       Date:  2016-11-22       Impact factor: 66.675
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.